288 related articles for article (PubMed ID: 22091432)
21. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.
Candolfi M; Kroeger KM; Xiong W; Liu C; Puntel M; Yagiz K; Muhammad AG; Mineharu Y; Foulad D; Wibowo M; Assi H; Baker GJ; Lowenstein PR; Castro MG
Anticancer Agents Med Chem; 2011 Oct; 11(8):729-38. PubMed ID: 21707497
[TBL] [Abstract][Full Text] [Related]
22. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.
Mégalizzi V; Mathieu V; Mijatovic T; Gailly P; Debeir O; De Neve N; Van Damme M; Bontempi G; Haibe-Kains B; Decaestecker C; Kondo Y; Kiss R; Lefranc F
Neoplasia; 2007 May; 9(5):358-69. PubMed ID: 17534441
[TBL] [Abstract][Full Text] [Related]
23. Design of new protein drug delivery system (PDDS) with photoactive compounds as a potential application in the treatment of glioblastoma brain cancer.
de Melo MT; Piva HL; Tedesco AC
Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110638. PubMed ID: 32204072
[TBL] [Abstract][Full Text] [Related]
24. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
25. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
26. [New therapeutic options in therapy of glioblastoma multiforme].
Lakomý R; Burkon P; Burkonová D; Jancálek R
Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
[TBL] [Abstract][Full Text] [Related]
27. Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme.
Persson O; Salford LG; Fransson J; Widegren B; Borrebaeck CA; Holmqvist B
J Neurooncol; 2010 Apr; 97(2):207-15. PubMed ID: 19809793
[TBL] [Abstract][Full Text] [Related]
28. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
Loew S; Schmidt U; Unterberg A; Halatsch ME
Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
[TBL] [Abstract][Full Text] [Related]
29. Immunotoxins and central nervous system neoplasia.
Hall WA; Fodstad O
J Neurosurg; 1992 Jan; 76(1):1-12. PubMed ID: 1727147
[TBL] [Abstract][Full Text] [Related]
30. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
32. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
33. Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme.
Arévalo ÁST; Erices JI; Uribe DA; Howden J; Niechi I; Muñoz S; Martín RS; Monrás CAQ
Curr Med Chem; 2017; 24(25):2781-2795. PubMed ID: 28260500
[TBL] [Abstract][Full Text] [Related]
34. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
35. Current and emerging EGFR therapies for glioblastoma.
Artene SA; Tuţă C; Dragoi A; Alexandru O; Stefana Oana P; Tache DE; Dănciulescu MM; Boldeanu MV; Siloşi CA; Dricu A
J Immunoassay Immunochem; 2018; 39(1):1-11. PubMed ID: 29308973
[TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
37. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.
Taylor OG; Brzozowski JS; Skelding KA
Front Oncol; 2019; 9():963. PubMed ID: 31616641
[TBL] [Abstract][Full Text] [Related]
39. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
40. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
